Cargando…
P030: Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642049/ http://dx.doi.org/10.1097/01.HS9.0000890688.01421.7a |
| _version_ | 1784826219792957440 |
|---|---|
| author | Romano, Alessandra Cerchione, Claudio Santuccio, Gabriella Le Moli, Marialudovica Chiarenza, Annalisa Figuera, Amalia Motta, Giovanna Caruso, L. Lanza, Sofia Petronaci, A. Poidomani, S. Ippolito, Massimo Di Raimondo, Francesco |
| author_facet | Romano, Alessandra Cerchione, Claudio Santuccio, Gabriella Le Moli, Marialudovica Chiarenza, Annalisa Figuera, Amalia Motta, Giovanna Caruso, L. Lanza, Sofia Petronaci, A. Poidomani, S. Ippolito, Massimo Di Raimondo, Francesco |
| author_sort | Romano, Alessandra |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9642049 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96420492022-11-14 P030: Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i Romano, Alessandra Cerchione, Claudio Santuccio, Gabriella Le Moli, Marialudovica Chiarenza, Annalisa Figuera, Amalia Motta, Giovanna Caruso, L. Lanza, Sofia Petronaci, A. Poidomani, S. Ippolito, Massimo Di Raimondo, Francesco Hemasphere Genomics, Biology & Microenvironment Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9642049/ http://dx.doi.org/10.1097/01.HS9.0000890688.01421.7a Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Genomics, Biology & Microenvironment Romano, Alessandra Cerchione, Claudio Santuccio, Gabriella Le Moli, Marialudovica Chiarenza, Annalisa Figuera, Amalia Motta, Giovanna Caruso, L. Lanza, Sofia Petronaci, A. Poidomani, S. Ippolito, Massimo Di Raimondo, Francesco P030: Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i |
| title | P030: Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i |
| title_full | P030: Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i |
| title_fullStr | P030: Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i |
| title_full_unstemmed | P030: Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i |
| title_short | P030: Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i |
| title_sort | p030: baseline igm amount can identify patients with adverse outcome despite a pet-2 adapted treatment in classical hodgkin lymphoma: results from a real-life single-center study i |
| topic | Genomics, Biology & Microenvironment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642049/ http://dx.doi.org/10.1097/01.HS9.0000890688.01421.7a |
| work_keys_str_mv | AT romanoalessandra p030baselineigmamountcanidentifypatientswithadverseoutcomedespiteapet2adaptedtreatmentinclassicalhodgkinlymphomaresultsfromareallifesinglecenterstudyi AT cerchioneclaudio p030baselineigmamountcanidentifypatientswithadverseoutcomedespiteapet2adaptedtreatmentinclassicalhodgkinlymphomaresultsfromareallifesinglecenterstudyi AT santucciogabriella p030baselineigmamountcanidentifypatientswithadverseoutcomedespiteapet2adaptedtreatmentinclassicalhodgkinlymphomaresultsfromareallifesinglecenterstudyi AT lemolimarialudovica p030baselineigmamountcanidentifypatientswithadverseoutcomedespiteapet2adaptedtreatmentinclassicalhodgkinlymphomaresultsfromareallifesinglecenterstudyi AT chiarenzaannalisa p030baselineigmamountcanidentifypatientswithadverseoutcomedespiteapet2adaptedtreatmentinclassicalhodgkinlymphomaresultsfromareallifesinglecenterstudyi AT figueraamalia p030baselineigmamountcanidentifypatientswithadverseoutcomedespiteapet2adaptedtreatmentinclassicalhodgkinlymphomaresultsfromareallifesinglecenterstudyi AT mottagiovanna p030baselineigmamountcanidentifypatientswithadverseoutcomedespiteapet2adaptedtreatmentinclassicalhodgkinlymphomaresultsfromareallifesinglecenterstudyi AT carusol p030baselineigmamountcanidentifypatientswithadverseoutcomedespiteapet2adaptedtreatmentinclassicalhodgkinlymphomaresultsfromareallifesinglecenterstudyi AT lanzasofia p030baselineigmamountcanidentifypatientswithadverseoutcomedespiteapet2adaptedtreatmentinclassicalhodgkinlymphomaresultsfromareallifesinglecenterstudyi AT petronacia p030baselineigmamountcanidentifypatientswithadverseoutcomedespiteapet2adaptedtreatmentinclassicalhodgkinlymphomaresultsfromareallifesinglecenterstudyi AT poidomanis p030baselineigmamountcanidentifypatientswithadverseoutcomedespiteapet2adaptedtreatmentinclassicalhodgkinlymphomaresultsfromareallifesinglecenterstudyi AT ippolitomassimo p030baselineigmamountcanidentifypatientswithadverseoutcomedespiteapet2adaptedtreatmentinclassicalhodgkinlymphomaresultsfromareallifesinglecenterstudyi AT diraimondofrancesco p030baselineigmamountcanidentifypatientswithadverseoutcomedespiteapet2adaptedtreatmentinclassicalhodgkinlymphomaresultsfromareallifesinglecenterstudyi |